Home > Boards > US Listed > Medical - Drugs > GlaxoSmithKline (GSK)

New NY-ESO-1 TCR-T data https://jitc.bmj.com/content/7/1/276

Public Reply | Private Reply | Keep | Last ReadPost New MsgPrevious | Next
jondoeuk Member Profile
 
Followed By 18
Posts 1,664
Boards Moderated 1
Alias Born 10/24/15
160x600 placeholder
CureVac right-sizes COVID-19 vaccine manufacturing in response to changes in demand Seeking Alpha - 9/14/2021 8:10:27 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 9/13/2021 1:49:57 PM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 9/9/2021 12:36:10 PM
Dosing underway in Alector's Phase 2 AL001 study in amyotrophic lateral sclerosis Seeking Alpha - 9/9/2021 9:44:57 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 9/7/2021 1:38:17 PM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 9/3/2021 7:19:10 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 9/1/2021 9:12:53 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 8/31/2021 8:04:42 AM
GlaxoSmithKline, SK Bioscience Begin Phase 3 Trial of Covid-19 Vaccine Dow Jones News - 8/31/2021 2:50:00 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 8/25/2021 9:44:47 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 8/23/2021 12:55:49 PM
Merck KGaA halts mid-stage trial for bintrafusp alfa in biliary tract cancer Seeking Alpha - 8/23/2021 12:03:22 PM
AnaptysBio Up 10% on GSK Drug Indication Approval Dow Jones News - 8/17/2021 6:50:00 PM
Amended Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k/a) Edgar (US Regulatory) - 8/13/2021 7:07:24 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 8/11/2021 10:02:12 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 8/11/2021 8:50:54 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 8/5/2021 7:30:18 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 8/2/2021 9:47:56 AM
GSK announces FDA approval for Nucala (mepolizumab) for use in adults with chronic rhinosinusitis with nasal polyps Business Wire - 7/29/2021 6:03:00 PM
GlaxoSmithKline announces FDA approval of Nucala for new eosinophilic-driven indication Seeking Alpha - 7/29/2021 3:04:24 PM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 7/28/2021 1:36:39 PM
GlaxoSmithKline 2Q Net Profit Fell Despite Higher Sales; Backs 2021 Outlook -- Update Dow Jones News - 7/28/2021 8:52:00 AM
GlaxoSmithKline posts Q2 earnings beat, maintains FY forecast Seeking Alpha - 7/28/2021 8:20:29 AM
GlaxoSmithKline 2Q Net Profit Drops Despite Higher Sales; Backs 2021 Outlook Dow Jones News - 7/28/2021 7:39:00 AM
GlaxoSmithKline, Vir Biotechnology to Supply Covid-19 Treatment to European Commission Dow Jones News - 7/28/2021 7:18:00 AM
jondoeuk   Saturday, 06/05/21 12:24:48 PM
Re: None
Post # of 167 
New NY-ESO-1 TCR-T data https://jitc.bmj.com/content/7/1/276

From it: ''These data provide an initial rationale as to how tumors with histologies resistant to checkpoint blockade can be successfully targeted with adoptive T-cell therapy. Furthermore, these data are the first to demonstrate successful infiltration of solid tumors by SPEAR T cells, which are able to kill tumor cells. Our data also suggest that antigen loss or alterations in the expression of antigen processing proteins are not primary mechanisms of resistance. Moreover, the therapeutic efficacy may be enhanced through use of a high dose fludarabine-containing preparative lymphodepletion regimen, by promoting greater engraftment at the tumor site, and through modulation of TAM.''

Public Reply | Private Reply | Keep | Last ReadPost New MsgPrevious | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences